TRIPOS RAISES $5.5 MILLION FROM SALE OF CONVERTIBLE

Tripos, Inc., a leading provider of drug discovery chemistry and informatics products and services, today announced that it has completed the sale of 1.8 million shares of Convertible Preferred Stock at a price of $3.00 per share and issued 550,000 five-year common stock warrants exercisable at $3.50 per share to Midwood Capital, a Boston-based investment partnership. The shares of Convertible Preferred Stock represent approximately 18 percent of Tripos' outstanding common stock on an as-converted basis.
Genetic Engineering News